Premium
Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents
Author(s) -
Cefalu W T
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100156
Subject(s) - medicine , glycemic , type 2 diabetes , incretin , diabetes mellitus , insulin , clinical pharmacology , pharmacotherapy , type 2 diabetes mellitus , insulin resistance , intensive care medicine , diabetes treatment , pharmacology , bioinformatics , endocrinology , biology
Type 2 diabetes, the most common form of diabetes, is characterized by abnormalities in hepatic glucose production, insulin resistance, and a progressive decline in β ‐cell function over time. To treat effectively the individual with type 2 diabetes, the provider must have a thorough understanding of the underlying pathophysiology to provide treatment that precisely addresses the metabolic abnormalities. Currently, the provider who cares for subjects with type 2 diabetes can choose an antidiabetic agent from no less than eight pharmacologic classes. These classes include agents that increase insulin secretion, improve insulin action, and delay absorption of carbohydrates. The newer treatments available, specifically incretin therapy, address a previously unmet need in diabetes by modulating glucose supply. The currently available agents can be combined and combination therapy markedly improves glycemic control. This allows the provider to design regimens to specifically address underlying abnormalities. A review of all currently available agents is provided. There is an Erratum associated with this State of the Art. Please see the PDF for details. Clinical Pharmacology & Therapeutics (2007) 81 , 636–649. doi: 10.1038/sj.clpt.6100156